Current Trainees

Elias K. Awad, M.D.

Elias K. Awad, M.D.

Elias K. Awad, M.D., graduated from University of South Alabama College of medicine in May of 2019. he is currently working with Dr. Deeann Wallis in the Department of Genetics. His research focuses on Neurofibromatosis 1 (NF1), specifically exon skipping and a potential novel treatment to reinstate normal splicing. In addition, another project he is working on looks at protein binding partners of NF1 in different cell lines and different mutation genotypes.

Michael Daniel, Ph.D.

Michael Daniel, Ph.D.

Michael Daniel, Ph.D., recently graduated from the University of Alabama at Birmingham in December 2017. He is currently working with Dr. Deeann Wallis in the Department of Genetics, UAB. His research focuses primarily on neurofibromatosis (NF1) and the implementation of exon skipping as a potentially novel treatment mechanism. In addition, his current project focuses on gene editing through the introduction of ribozymes.

Mary Smithson, M.D.

Mary Smithson, M.D.

Mary Smithson, M.D., graduated from the University of Alabama Birmingham School of Medicine in June of 2018. She has completed 2 years of general surgery residency at UAB and is now taking 2 years for research before returning to clinical work. She is currently working with Dr. Karin Hardiman in the Department of GI Surgery at UAB. Her research focuses on mechanisms of radiation resistance in rectal cancer using single cell sequencing. 

John Soldner, Pharm.D.

John Soldner, Pharm.D.

John Soldner, Pharm. D., graduated with his Doctor of Pharmacy from Samford University’s McWhorther School of Pharmacy in May 2019. He is currently working with Dr. John Hartman in the Department of Genetics, UAB. His postdoctoral work involves the application of novel systems biology and gene interaction discovery techniques in yeast, which he is applying to p53 and cancer-associated p53 mutations, as well as to pharmacogenomics/pharmacology to predict how differential gene expression unique to cancer can render it vulnerable to specific chemotherapeutic agents. Using this yeast phenomic paradigm for modeling questions in human disease, the goal is to explore the possibility of precision medicine on a more global scale.

Past Trainees

Miranda Burnette, Ph.D.

Miranda Burnette, Ph.D.

J. Nicholas Cochran, Ph.D.

J. Nicholas Cochran, Ph.D.

Kyle Feeley, Ph.D.

Kyle Feeley, Ph.D.

Kyle Feeley, Ph.D.

Kyle Feeley, Ph.D.

Nadiya Sosonkina, Ph.D.

Nadiya Sosonkina, Ph.D.

Megan Brietbach, Ph.D.

Megan Brietbach, Ph.D.

Brittney Davis, Pharm.D.

Brittney Davis, Pharm.D.